Vijaya Diagnostic Centre Reports Q1 Net Profit of 531m Rupees on Revenue of 2.31b

Market snapshot: Vijaya Diagnostic Centre Limited has announced its financial results for the first quarter ended June 30, 2026. The diagnostic chain registered robust growth across all major performance metrics, highlighting a strong start to the financial year.

Data Snapshot

• Consolidated revenue from operations grew by 22.8% year-on-year to ₹231 crore.
• Consolidated Profit After Tax increased by 37.6% year-on-year to ₹53.1 crore.
• Consolidated EBITDA grew by 34.0% year-on-year to ₹98.5 crore with EBITDA margin expanding 360 bps to 42.7%.

What's Changed

• Revenue expanded sequentially to ₹231 crore, representing a 5.48% QoQ increase from the prior-quarter (Q4 FY26) revenue of ₹219 crore.

Key Takeaways

• Significant double-digit volume growth with total test volumes up 16.5% year-on-year.
• High profitability resilience, bolstered by operational efficiencies as EBITDA margins rose to 42.7% from 39.1% YoY.
• Strong direct consumer focus with the Business-to-Consumer (B2C) segment driving 92% of the total revenue mix.
• Footfall growth remained robust, with total footfalls reaching 1.24 million and tests performed crossing 4.59 million during the quarter.

SAHI Perspective

Vijaya Diagnostic's performance reflects the scaling of its integrated diagnostics model, which provides both radiology and pathology under one roof. The superior margin structure is a direct result of strong consumer focus (92% B2C) and expanding scale in adjacent markets like Pune and Bengaluru, where newly added centers are tracking ahead of schedule towards operational break-even.

Market Implications

The strong quarterly update will likely improve near-term investor sentiment for diagnostics stocks, indicating that organized chains are steadily clawing back market share through volume gains and technological edge, even amid competitive pricing environments.

Trading Signals

Market Bias: Bullish

The diagnostic chain delivers strong double-digit growth across revenue (up 22.8% to ₹231 crore) and net profits (up 37.6% to ₹53.1 crore). Sustained operational leverage and sequential revenue expansion support a constructive outlook.

Overweight: Healthcare, Diagnostics

Trigger Factors:

• Faster-than-expected operational break-even of the newly launched JP Nagar (Bengaluru) and Gachibowli (Hyderabad) hubs.
• Sustained B2C contribution of above 90% protecting EBITDA margins in the range of 40-42%.
• Successful integration of advanced radiology software and AI workflows to optimize turnaround times.

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian diagnostic sector is consolidating around organized players who leverage superior radiology-pathology integration. Organized chains are scaling beyond core geographic strongholds by introducing state-of-the-art regional hubs, which serve as feeder systems for lower-overhead spoke centers.

Key Risks to Watch

• Intensifying pricing competition in the routine pathology segment from online aggregators.
• Geographic concentration risks, as the company remains highly dependent on the Hyderabad and wider South Indian markets for the bulk of its revenue.

Recent Developments

Vijaya Diagnostic Centre has accelerated its expansion by launching a flagship hub in JP Nagar, Bengaluru, in July 2026, equipped with high-end diagnostic tools like a Wide Bore 3T Omega MRI and digital PET-CT. In addition, the company established a hub in Gachibowli, Hyderabad, in April 2026, alongside new spokes in Hyderabad, Andhra Pradesh, and Pune. The company also announced a dividend of Re. 2 per share for FY26, with its AGM scheduled for August 14, 2026.

Closing Insight

With strong cash generation and a highly profitable hub-and-spoke expansion framework, Vijaya Diagnostic is proving that high-end radiology capabilities can effectively insulate regional diagnostic giants from pure-play pathology price wars.

High Performance Trading with SAHI.